DOCSLIB.ORG

Berrchem Company Ltd API List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Berrchem Company Ltd API List Berrchem Company Ltd API List 136470-78-5 Aba cavir 154229-19-3 Abiraterone 226954-04-7 AC-5216 57960-19-7 Ace qui nocyl 6622-91-9 4-(A cetic A cid) Pyridine hydr ochloride 5 -Acetylamino-2-a min o-4-picoli ne 93273-63-3 4-Acetyl-2-bromobenz onitrile 49 669 -13-8 2-A cetyl-6-bromopyridine 561 72-71-5 1-Acetyl-cycl opropane carboxylic aci d 57 756 -36-2 4-Acetyl -2,3,4, 5-tetrahydr o-1H-1, 4-benz odiaz epine 550 79-83-9 Acitretin 55077-30-0 Aclatonium napadisilate 10523-68-9 2-A dama ntanami ne hydrochlori de 10 6941 -25-7 Adefovir 1991-10-1 aldrich 80863-62-3 A LITAME 315-30-0 Allopurinol 850649-62-6 Alogliptin benzoat e 25526-93-6 Alovudi ne 8 50-52-2 ALT RENOGEST 645-05-6 Altretami ne 177036-94-1 AMBRISENTAN 61618-27-7 Amfe nac sodi um 773 7-17-9 Ami noacetone hydr ochl oride 2498 -50-2 4-A minobenzami dine Dihydrochlori de 3 7141-01-8 1-A minobenzene -3,4, 5-tricarboxylic acid 23031-78-9 3-A mino -1, 2- benzisothiazole 7644-4-4 2-Ami no -4’-bromoa cetophenone HCl 20776-51-6 2-a mino -3-bromobenzoic aci d 135776-98-6 (2-A mino -4-bro mo -phenyl)-phenyl-metha none 2-Amin o-4’-chlor oacetophe none HCl salt 89604-91-1 7-Ami no -3-Chl oro Cephalos porani c Acid 5399 4-69-7 7-Amin o-3-Chlor o Cephal ospora nic Acid 112 885 -41-3 4-A mino -5-chloro-2-etho xy-N-((4 -(4-fluor obe nzyl)-2-morpholinyl)methyl)benza mide 100371 0-83-5 2-Amin o-5-chlor o-4-fluor o-3-hydr oxypyridi ne 14394-56-0 6-A mino -4-Chl oro -5-M ethylpyrimidi ne 51564 -92-2 2-A min o-6-chloro -4-pi coline 58483-95-7 5-AMI NO-2-CHLO RO PYRIDI NE-4-CA RBOXY LIC ACID 214353-17-0 2'-A mino -5'-chl oro-2,2,2-trifluoroacetophenone hydrochl oride monohydrate 6850 -39-1 3-A mino -cy clohexanol 107017-72-1 1-A mino -cy clopr opanemet hanol 161 735 -79-1 1-A mino -cy clopr opanemet hanol 107 017 -72-1 1-A mino -cy clopr opanemet hanol HCl 127946-77-4 1-A mino -Cy clopr opyl Cyanic Hydrochlori de 3 7148 -48-4 4-A mino -3,5-di chlor oacet ophenone 1 7377 2-63-9 3-A min o-2,4-dichl oropyridi ne 5 177 -27-5 5-A mino -2,4-di chlor opyrimi dine 933 -20-0 2-a mino -4,6-dichlor otriazine 86209-44-1 2-Amin o-4,6-difluoromethoxypyri midine 49 701 -24-8 4-AMINO-2,5-DIMETH OXY -N-METHYLBENZENE S ULFONAMIDE 5018-45-1 4-AMI NO-5,6-DIMET HOXY PY RIMIDI NE 40963-14-2 "2 -Ami no -2,3-di methylbuta cetami de " 514 68-00-9 3-A mino -5-ethoxypyridine 369 -43-7 2-Ami no -4’ -fluoroa cetophenone HCl 9142 23-43-1 3-Amin o-2-fluor obe nzoi c a cid 446 -31-1 4-A mino -2-fluorobenzoic acid 434-76-4 2-ami no -6-fluorobe nz oic a cid (6 -fluoroanthranilic acid) 859855-53-1 3-Ami no -4-fluorobenzonitrile 80517-22-2 2-A mino -4-fl uorobenz onitrile 1 0037 10-90-4 2-Amin o-4-fluor o-3-hy droxy pyridine 2 -Ami no -5-flu oro -3-hydroxypyridine 6 2257 -16-3 3-a mino -4- fluor ophe nol 5398 1-24-1 2-Amin o-5-fluor ophe nol 91422 4-31-0 2-(4 -Ami no -2-fluorophenyl) aceti c aci d 173435-32-0 3-Ami no -2-flu oro-4-picoli ne 18614-51-2 4-Ami no -2-fluoropyridine 1597-33-7 3-A min o-2-fluoropyridine 1978 -33-2 3-A mino -2-flu oro -tolue ne 44 3-89-0 2-A min o-3-Fluor otolue ne 2 984 0-65-1 7-a mino -he ptanoi c aci d ethyl e ster HCL 18802-38-5 6-Ami no -2H -[1,2,4]triazine-3,5-dione 45 4-81-9 3-ami no-4-hydroxybenzotrifl uoride 6580 2-56-4 "4 -Amin o-6-hydroxy-2-mer captopyrimidi ne monohydrate " 10 04-40-6 " 6-a mino -4-hydr oxy -2-mer capto -pyrimi dines " N/A 4 -Aminoimidazole HCl 1450-93-7 2-Ami noimi dazol e he misul fate 62 041 -01-4 3-a mino -4-iminorifamycin-S 27473-62-7 2-Ami no -2-Indancarboxylic acid 150544-04-0 6-a minoi ndoli n-2-one 1297222 5-Aminolevulini c aci d Hydrochl oride 1 4893 2-68-7 2-a min o-3-metho xy-benzonitrile 64436-92-6 3-A min o-5-methoxypyridine 3880-88-4 2-a min o-5-methoxytetralin HCl 2305-37-5 5-Amin o-3-methylbe nzoi c aci d 239 3-20-6 "3-A min omet hyl-benzoic acid HCl salt " 15996-76-6 4-(Aminomethyl)benzonitrile HCl 368426-86-2 5-(AMINOMETHYL)-2-F LUOROBE NZONITRI LE 289483-87-0 7-Amino-4-methyl-1H-i ndole -3-carbonitrile 130912-52-6 (+/ -)-3-(A mino methyl )-5-Methylhexa noic a cid 1 6216 7-97-7 3-(AMINOMETHYL)-1-N-BO C-PIPE RIDINE-H Cl 370069-31-1 2-Amin omet hyl-pi peridine -1-carboxylic acid tert -butyl ester 3 430 -19-1 3-Amin o-5-methylpyridine 1795 55-11-4 2-A min o-4-methyl-5-pyridinecarboxylic acid 1000796-62-2 (+ / -)-3-AMI NO-1-N-BOC-PIPE RIDI NE-citrate 186550-13-0 (+/ -)-3-AMINO-1-N-BOC -PY RROLIDINE -citrate 212268-12-7 2-Ami no-3-nitro-5-fluoropyridine 85152 4-96-4 6-A minopyridine -3-bor onic a cid 827614-64-2 2-A minopyridine -5-boronic a cid pi nacol ester 752 1-41-7 2-A mino -3-pyridine carboxal dehyde 59315-44-5 3-a mino -pyridi n-2-ol 23612-57-9 (2 -Ami no -pyridin-3-yl)-metha nol 591 -54-8 4-a minopyrimidi ne (pyrimi din-4-a mine ) 862372-66-5 3-AMINO-PYRROLIDINE -1, 3-DI CARBOX YLI C ACID 1 -TERT -BUTYL ESTER 144550-79-8 2-(AMINOS ULFONYL)-4-I OD OBE NZOIC ACID METHY L ESTE R 410 0-41-8 5-AMINO-1, 2, 3-THIADIAZOLE 17721-06-1 3-AMI NOT HIOP HENE n/a 2-A mino -4' -tolylacetophenone hydrochl oride 83265 -53-6 2-A min o-5-(Tri fluor omethyl)be nz oic a cid 37885-07-7 1-[2 -ami no -4-(trifluoromethyl)phe nyl]-Et hanone 5 8579 -51-4 A nagrelide hydrochloride 16 6663 -25-8 A nidula fungi n 17 072 9-80-3 Aprepitant 86780-90-7 Aranidi pine 730 80-51-0 Aripiprazole 23964-57-0 Articaine hydrochlori de 2 29975 -97-7 Atazanavir sul fate 72217-12-0 ATDA:( Z ) -2-(5-a min o-1, 2,4-t hiadiazol-3-yl)-2-methoxyi mino acetic aci d 104054-27-5 Atipa mezole 134523-03-8 atorvastatine calcium salt 55-48-1 Atropine Sulfate 319460-85-0 A xitinib 104239-97-6 4-Aza-5a -androstan-1-en-one-16b-car bo xylic acid 130931-83-8 (+ )-2-Azabi cyclo[2.2 .1]hept -5-en-3-one 2 71-29-4 6-Azai ndole 272 -49-1 4-A zaindole 5-Azai ndol e 86-50-0 Azinphosmethyl 83905-01-5 azithromyci n 97404-02-9 Basic orange 31 198481-33-3 Ba zedoxi fene a cetate 86541-74-4 Bena zepril H Cl 5470-49-5 Benze nea mine, 4 -methylsulfonyl- 21606-04-2 1, 2-Benzenedicarboxylicacid, 3-nitro-1-methylester No 1,3-benzene disul foni c acid, 4-[[(1,1 -di methylethyl)oxi doi mino]methyl]-,disodium salt 554-95-0 1,3,5-Benzene tricarboxylic acid 3469-6-5 benz ocycl obutenone 105684-23-9 1-(BENZO [D ][1 ,3]D IOX OL -4-YL)PI PERAZINE H YDROCH LORIDE 59247-47-1 Benz oic a cid, 4 -bro mo -, 1,1-di methylethyl ester 113100-81-5 Benz oic a cid,4 -(3 -oxopropyl )-, methyl ester 51135-38-7 7-Be nzoyl -1,3-dihydr o-i ndol -2-one 3070-71-1 2-Benzyl Acrylic a cid methyl Acepromazine Maleate cas#: 3598-37-6 ester 83507-33-9 3-be nzyl-3-aza bicycl o[3 ,2,1 ]o ctan-8-one 106848-38-6 1-Be nzyl-4-Bromoimi dazole 2867 -63-2 2-Be nzyl-cyclopenta none 2057 0-96-1 Ben zyl-hydrazi ne di hydrochloride 9485 49-60-8 4-(be nzyloxy)-5-bro mo -2-a minopyrimi dine 28 30-53-7 1-(benzyloxy)-2-bro mo -4-methylbenze ne 207296-89-7 4-Benzyloxycar bonyla minopiperidi ne HCl 1 9916 -73-5 6-Be nzyloxy guanine 179688-01-8 7-Ben zyloxy -6-met ho xy-3H -quinazolin-4-one 85098-64-2 1-benzyl-4-(phe nylamino)pi peridine-4-carboxylic acid 84477-71-4 2-BENZY L-PI PERAZI NE 50606-58-1 1-Ben zyl-3-piperi done hydrochlori de 56 -37-1 Benz yltriethylammoni um chlori de 190 786 -44-8 Bepotastine Besilate 478-61-5 Berba mine Hydrochloride 2086 -83-1 Berberine HCl No beta -Methyl vinyl phosphate (MAP ) 473 -98-3 Betulin: Lup-20(29)-ene -3,28-di ol,(3b) 90357-06-5 Bicalutamide N/A Bicy clo[4.2.0]octa-1 (6 ),2,4 -triene -3-carbonitrile 393-75- 9 "3,5-binitro-4-chlorobenz otrifluoride " 3697 8-41-3 2,3,3', 4'-bi phe nyl tetracarboxylic dia nhydride 378 5-34-0 1,2-Bis(Br omoacetoxy)et hane 32005-36-0 Bis (dibe nzylide neacetone ) palladi um(0) 7133 7-53-6 Bis (3,5 -dibromosalicyl)fumarate 3033-62-3 " Bis (2-dimethylaminoethyl)et her " 73183-34-3 Bis(pi nacolato)di boron 171 557 -31-6 (Bis -tert-butoxycarbonylmet hyl-ami no )-a cetic a cid 3 2315 -10-9 Bis(trichloromethyl) carbonate 132810-10-7 Blonanserin 104195-80-4 Bo c-allo-O-methyl-D -Thr 129786-68-1 Bo c-al pha -allyl-D-Ala 166104-20-7 1-Bo c-5-A minoindole 142253-55-2 Boc-azetidine-3-carboxylic acid n/a Boc-beta-N-methyla mino -L-Ala 82278-73-7 Bo c-L-3-Br omophenylalanine Boc-N-Me-Tyr -OH .
Load more

Recommended publications
  • Dejong Autman
    King’s Research Portal Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): De Jong, S., Vidler, L., Mokrab, Y., Collier, D. A., & Breen, G. D. (Accepted/In press). Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. Journal of Psychopharmacology. Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Protective Role of Parnaparin in Reducing Systemic Inflammation and Atherosclerotic Plaque Formation in Apoe-/- Mice
    INTERNATIONAL JOURNAL OF MoleCular MEDICine 27: 561-565, 2011 Protective role of parnaparin in reducing systemic inflammation and atherosclerotic plaque formation in ApoE-/- mice MARCO ArtiCO1, RACHELE RIGANÒ2, BRiGitta Buttari2, ELisabetta PROFUMO2, BRUNELLA Ionta1, sANDRO BOsCO3, MANUELA RASILE2, ENRiCA BiANCHi1, MOiRA BRUNO1 and LORENZO FUMAGALLI4 1Department of sensory Organs, University of Rome ‘sapienza’; 2Department of Infectious, Parasitic and Immuno-mediated Diseases of the superior Health institute of Rome; Departments of 3Experimental Medicine and 4Anatomical, Histological, Medico-legal and Locomotor system sciences, University of Rome ‘sapienza’, Rome, italy Received November 15, 2010; Accepted December 29, 2010 DOi: 10.3892/ijmm.2011.606 Abstract. Atherosclerosis is a degenerative disease whose Unstable atherosclerotic plaques are vulnerable to rupture, and role in the onset and development of cardiovascular patholo- usually contain an increased accumulation of inflammatory gies and complications is of importance. Due to its silent but cells, particularly macrophages and T-lymphocytes secreting progressive development, and considering the endothelial, growth factors (EGF and bFGF) and pro-inflammatory immunological and inflammatory processes that are involved cytokines (4-6). Rather than remaining localized within in its clinical course, this still relatively unknown pathological the ‘culprit’ plaque, the inflammatory components spread condition has been and continues to be a matter of investiga- throughout the peripheral blood. Several studies suggest an tion worldwide. Our experience with previous studies on association between pro-inflammatory cytokines (TNFα, IL-6, atherosclerosis led us to investigate the possible influence IL-1) in the peripheral blood of patients with atherosclerosis of a low molecular weight heparin (LMWH) – Parnaparin® and the clinical outcome or stage of atherosclerotic disease on the development and clinical course of atherosclerosis in (7-11).
    [Show full text]
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • IP Vol.2 No.2 Jul-Dec 2014.Pmd
    International Physiology63 Short Communication Vol. 2 No. 2, July - December 2014 Role of Polyol Pathway in Pathophysiology of Diabetic Peripheral Neuropathy: An Updated Overview Kumar Senthil P.*, Adhikari Prabha**, Jeganathan*** Abstract The aim of this short communication article was to enlighten the role of polyol pathway in pathophysiology of diabetic peripheral neuropathy (DPN) through an evidence-informed overview of current literature. Findings from experimental models of DPN suggest that altered glutathione redox state, with exaggerated NA(+)-K(+)-ATPase activity, increased malondialdehyde content, decreased red blood cell 2,3-diphosphoglycerate concentration, reduced cyclic adenosine monophosphate, reduced myo- inositol and excessive sorbitol in peripheral nerves were indicative of polyol metabolic pathwayin producing pathophysiological changes of DPN, and treatments using aldose reductase inhibitors were found to reverse those changes. Keywords: Polyol pathway; Myo-inositol; Sorbitol; Neurophysiology; Endocrinology. The aim of this short communication oxidized (GSSG) glutathione levels in crude article was to enlighten the role of polyol homogenates of rat sciatic nerve. The study pathway in pathophysiology of diabetic concluded that altered glutathione redox peripheral neuropathy (DPN) through an state played no detectable role in the evidence-informed overview of current pathogenesis of this defect in diabetic literature. peripheral nerve. Calcutt et al[1] measured motor nerve Finegold et al[3] studied the effect of conduction velocity (MNCV), Na(+)-K(+)- polyol pathway blockade with sorbinil, a ATPase activity, polyol-pathway specific inhibitor of aldose reductase, on metabolites, and myo-inositol in sciatic nerve myo-inositol content in acutely nerves from control mice, galactose-fed streptozotocin-diabetic ratswhich (20% wt/wt diet) mice, and galactose-fed completely prevented the fall in nerve myo- mice given the aldose reductase inhibitor inositol.
    [Show full text]
  • Phase II Study of Hormone Therapy with Tamoxifen in Patients with Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)
    Phase II study of hormone therapy with tamoxifen in patients with well differentiated neuroendocrine tumors and hormone receptor positive expression (HORMONET) Time of researchers and respective Departments: Rachel Riechelmann (Main Investigador)1, Milton Barros 1, Marcos Camandaroba1,2, Virgilio Souza1,2, Celso Abdon Mello1, Paula Nicole3, Eduardo Nóbrega4, Ludmilla Chinen5, Marina De Brot6, Héber Salvador7. Departaments: 1- Clinical Oncology; 2- postgraduate student; 3- Radiology; 4- Nuclear Medicine; 5-International Research Center (CIPE); 6-Pathologic anatomy; 7- Abdomen Surgery AC Camargo Cancer Center - Brazil Registration Number on Institutional Research Ethics Committee: 2626/18 March,06,2019 Introduction Neuroendocrine tumors (NET) are rare neoplasms, but with increasing incidence and prevalence in the last decades. Although they may manifest in the most diverse tissues, the vast majority of cases will affect organs of the digestive tract and lung. At diagnosis, more than half of the cases present metastatic disease, and among patients with localized disease, up to one-third will have recurrence of the disease. Unfortunately, the minority of patients with metastatic disease are eligible for curative intent.1 Although there are many types of NET, they are often studied together as a group because their cells share common histological findings, have special secretory granules, and the ability to secrete bioactive amines and polypeptide hormones. Approximately 25 percent of the tumors present functional hormonal syndromes (situation of great morbidity for these patients), being the carcinoid syndrome, the most common one. From the molecular point of view, these neoplasias are largely dependent on the activation of the mTOR pathway and neoangiogenesis.2 Another striking feature of neuroendocrine cells is the expression of cell surface hormone receptors whose activation or blockade may exert an important regulatory function.
    [Show full text]
  • Effects of Chronic Systemic Low-Impact Ampakine Treatment On
    Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi Et Al
    US 2004O116357A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0116357 A1 Fushimi et al. (43) Pub. Date: Jun. 17, 2004 (54) GLUCOPYRANOSYLOXYPYRAZOLE DERVATIVES AND MEDICINAL USE THEREOF (I) (76) Inventors: Nobuhiko Fushimi, Matsumoto-shi (JP); Hideki Fujikura, Matsumoto-shi (JP); Toshihiro Nishimura, Minamiazumi-gun (JP); Kenji Katsuno, Kamiina-gun (JP); Masayuki Isaji, Shiojiri-shi (JP) Correspondence Address: SUGHRUE MION, PLLC 2100 PENNSYLVANIAAVENUE, N.W. SUTE 800 WASHINGTON, DC 20037 (US) (21) Appl. No.: 10/469,140 (22) PCT Filed: Feb. 26, 2002 (86) PCT No.: PCT/JP02/01708 wherein R', R and R represent a hydrogen atom or a (30) Foreign Application Priority Data halogen atom; R" represents a lower alkyl group or a halo(lower alkyl) group; and R represents a hydrogen atom, Feb. 27, 2001 (JP)...................................... 2001-053085 a lower alkyl group, a lower alkoxy group, a lower alkylthio group, etc., a pharmaceutically acceptable Salt thereof or a Publication Classification prodrug thereof., which exert an excellent inhibitory activity (51) Int. Cl. ................................................ A61K 31/7056 in human SGLT2, and therefore are useful as drugs for the (52) U.S. Cl. ............................................. 514/23: 536/17.4 prevention or treatment of a disease associated with hyper glycemia Such as diabetes, diabetic complications or obesity, (57) ABSTRACT pharmaceutically acceptable Salts thereof or prodrugs The present invention provides glucopyranosyloxypyrazole thereof, production intermediates thereof and pharmaceuti derivatives represented by the general formula: cal uses thereof. US 2004/0116357 A1 Jun. 17, 2004 GLUCOPYRANOSYLOXYPYRAZOLE 0005. In recent years, development of new type antidia DERVATIVES AND MEDICINAL USE THEREOF betic agents has been progressing, which promote urinary glucose excretion and lower blood glucose level by prevent TECHNICAL FIELD ing excess glucose reabsorption at the kidney (J.
    [Show full text]
  • Nicotinic Receptors in Neurodegeneration
    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]